Blueprint Medicines Corp (BPMC)
106.25
-0.94
(-0.88%)
USD |
NASDAQ |
May 06, 16:00
106.24
-0.01
(-0.01%)
After-Hours: 20:00
Blueprint Medicines Cash from Investing (Quarterly): 77.13M for March 31, 2024
Cash from Investing (Quarterly) Chart
Historical Cash from Investing (Quarterly) Data
| Date | Value |
|---|---|
| March 31, 2024 | 77.13M |
| December 31, 2023 | 78.77M |
| September 30, 2023 | -9.586M |
| June 30, 2023 | 32.07M |
| March 31, 2023 | 172.79M |
| December 31, 2022 | -53.28M |
| September 30, 2022 | -132.24M |
| June 30, 2022 | 77.07M |
| March 31, 2022 | -41.09M |
| December 31, 2021 | -346.95M |
| September 30, 2021 | 104.07M |
| June 30, 2021 | -115.18M |
| March 31, 2021 | 132.20M |
| December 31, 2020 | -75.53M |
| September 30, 2020 | -430.14M |
| June 30, 2020 | 11.56M |
| March 31, 2020 | 59.86M |
| December 31, 2019 | 67.74M |
| September 30, 2019 | 74.54M |
| June 30, 2019 | -248.05M |
| March 31, 2019 | 89.31M |
| Date | Value |
|---|---|
| December 31, 2018 | 56.24M |
| September 30, 2018 | 16.59M |
| June 30, 2018 | -14.79M |
| March 31, 2018 | -219.13M |
| December 31, 2017 | 49.87M |
| September 30, 2017 | -7.871M |
| June 30, 2017 | -150.14M |
| March 31, 2017 | 35.79M |
| December 31, 2016 | -138.29M |
| September 30, 2016 | -15.62M |
| June 30, 2016 | 5.448M |
| March 31, 2016 | -70.36M |
| December 31, 2015 | -3.684M |
| September 30, 2015 | -0.822M |
| June 30, 2015 | -0.288M |
| March 31, 2015 | -1.285M |
| December 31, 2014 | -0.399M |
| September 30, 2014 | -0.189M |
| June 30, 2014 | -0.018M |
| March 31, 2014 | -0.094M |
Cash From Investing Definition
Cash from Investing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall investing activities of the company. A few examples of investing activities include net change in PP&E, and net divestitures.
Cash from Investing (Quarterly) Range, Past 5 Years
-430.14M
Minimum
Sep 2020
172.79M
Maximum
Mar 2023
-28.21M
Average
21.81M
Median
Cash from Investing (Quarterly) Benchmarks
| Apellis Pharmaceuticals Inc | 0.004M |
| Alnylam Pharmaceuticals Inc | -67.62M |
| Ionis Pharmaceuticals Inc | -26.71M |
| Madrigal Pharmaceuticals Inc | -362.12M |
| Sarepta Therapeutics Inc | 218.80M |
Cash from Investing (Quarterly) Related Metrics
| Cash from Operations (Quarterly) | -101.51M |
| Cash from Financing (Quarterly) | 66.96M |
| Free Cash Flow | -429.98M |
| Free Cash Flow Per Share (Quarterly) | -1.608 |
| Free Cash Flow to Equity (Quarterly) | -103.19M |
| Free Cash Flow to Firm (Quarterly) | -96.73M |
| Free Cash Flow Yield | -6.58% |